Overview

Dose Optimisation of Stavudine for the Treatment of HIV Infection

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate whether low dose stavudine (d4T) is non-inferior (in terms of both viral suppression and toxicity) to tenofovir (TDF) after 2 years of HIV treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Willem Daniel Francois Venter
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Efavirenz
Lamivudine
Stavudine
Tenofovir